Mary Jeanne Kreek, MD
Rockefeller University, Kreek Lab
This study will examine functional variants in three genes (OPRM1, OPRK1, and PDYN) known to affect the dynamic response to opioid receptor ligands. These variants will be evaluated for their contribution to treatment retention, abstinence, and depression in the CTN-0051 trial. Their effects will be compared between the two alternative treatments: extended-release injectable naltrexone (XR-NTX) and buprenorphine-naloxone (BUP-NX). Pharmacogenomics application of study results obtained may allow individual tailoring of these medications. In addition, knowledge pertaining to other aspects of pathophysiology of the receptors systems targeted by XR-NTX or BUP-NX may be gained.
For the four gene variants evaluated in the study, there were no significant main effects of gene variant on receiving the first dose or last dose of XR-NTX or BUP-NX. There were also no significant gene variant by treatment interactions.
Primary Outcomes Article: Randesi M, et al. Variants of Opioid Genes and Response to Treatment of Opioid Use Disorder with Buprenorphine-Naloxone Versus Extended-Release Naltrexone in Caucasians. American Journal of Drug and Alcohol Abuse 2020;46(6):761-768. [get article]
- CTN-0051: Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT)
- CTN-0051-A-2: Treatment-As-Usual Opioid Use Outcomes Following Discharge from Detoxification and Short-Term Residential Programs Affiliated with CTN-0051
All Participating Nodes: